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Summary
Here, we provide evidence for a detrimental role of
tumor necrosis factor-related apoptosis-inducing li-
gand (TRAIL) in neural death in T cell-induced experi-
mental autoimmune encephalomyelitis (EAE), an ani-
mal model of multiple sclerosis (MS). Clinical severity
and neuronal apoptosis in brainstem motor areas
were substantially reduced upon brain-specific block-
ade of TRAIL after induction of EAE through adoptive
transfer of encephalitogenic T cells. Furthermore,
TRAIL-deficient myelin-specific lymphocytes showed
reduced encephalitogenicity when transferred to wild-
type mice. Conversely, intracerebral delivery of TRAIL
to animals with EAE increased clinical deficits, while
naive mice were not susceptible to TRAIL. Using or-
ganotypic slice cultures as a model for living brain
tissue, we found that neurons were susceptible to
TRAIL-mediated injury induced by encephalitogenic T
cells. Thus, in addition to its known immunoregula-
tory effects, the death ligand TRAIL contributes to
neural damage in the inflamed brain.
Introduction
Multiple sclerosis (MS) is a multiphasic autoimmune
disease of the CNS (Steinman, 2001) in which myelin-
specific CD4+ Th1 cells are thought to orchestrate the
effector processes resulting in the destruction of the
myelin sheath (Brosnan and Raine, 1996). Recent*Correspondence: frauke.zipp@charite.de
4 These authors contributed equally to this work.
5 These authors contributed equally to this work.studies in MS and its animal model, experimental auto-
immune encephalomyelitis (EAE), suggest, however,
that already during the early phase of inflammation,
neuronal pathology involving axonal transection plays a
pivotal role in disease pathology (Ferguson et al., 1997;
Kornek et al., 2000; Meyer et al., 2001; Trapp et al.,
1998). It has become evident that long-term disability
in MS correlates better with axonal damage than with
the degree of demyelination (Bjartmar et al., 2003). In
the EAE model, we have recently reported the occur-
rence of apoptotic neurons in the brainstem of affected
animals, indicating irreversible neuronal cell loss (Dies-
tel et al., 2003). However, the mechanisms of this neu-
ronal damage have to be elucidated, as they constitute
one of the main targets in the prevention of persisting
clinical deficits during autoimmune neuroinflammation
(Zamvil and Steinman, 2003).
Tumor necrosis factor (TNF)-related apoptosis-induc-
ing ligand (TRAIL), also known as Apo2 ligand, is a
member of the TNF/nerve growth factor (NGF) super-
family (Pitti et al., 1996; Wiley et al., 1995). In humans,
four membrane bound receptors for TRAIL have so far
been identified. Of these, only TRAIL receptor 1 (TRAIL-
R1 or death receptor 4 [DR4]) (Pan et al., 1997) and
TRAIL receptor 2 (TRAIL-R2, TRICK2, KILLER, DR5)
(Walczak et al., 1997) have the capacity to induce cas-
pase-dependent apoptotic cell death, whereas TRAIL-
R3 (DcR1) and TRAIL-R4 (DcR2) lack a functional death
domain and are considered to act as decoy receptors
(Degli-Esposti et al., 1997b; Degli-Esposti et al., 1997a).
In the murine system, two decoy receptors have been
reported recently (Schneider et al., 2003), whereas only
one death-mediating TRAIL receptor is known, which
has the highest homology with the human TRAIL recep-
tor 2 (Wu et al., 1999).
Initial reports indicated a specific and selective ac-
tion of TRAIL on transformed cells (Ashkenazi et al.,
1999; Walczak et al., 1999). They also provided evi-
dence for the role of TRAIL in the immunosurveillance
of tumor cells (Cretney et al., 2002; Smyth et al., 2001).
Expression of TRAIL has been shown for a variety of
immune cells, and T cells were found to upregulate
TRAIL upon antigen-specific stimulation (Mariani and
Krammer, 1998; Wendling et al., 2000). Systemic (in-
traperitoneal) injection of soluble neutralizing TRAIL-R2
(DR5) leads to exacerbation of murine collagen-
induced arthritis (Song et al., 2000), autoimmune diabe-
tes (Lamhamedi-Cherradi et al., 2003a), and myelin oli-
godendrocyte glycoprotein (MOG)-mediated EAE in
C57BL/6 mice (Hilliard et al., 2001). Moreover, recent
reports have discussed the possible contribution of
TRAIL to selection processes within the thymus (Cret-
ney et al., 2003; Lamhamedi-Cherradi et al., 2003b). We
have even shown that TRAIL is capable of inhibiting T
cell activity and is upregulated in MS patients respond-
ing to interferon-β therapy (Lünemann et al., 2002; Wan-
dinger et al., 2003).
Further research has revealed that TRAIL is also able
to induce apoptosis in nontransformed human cells, as
certain recombinant TRAIL preparations were cytotoxic
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422Figure 1. Autoimmune Encephalomyelitis Is Ameliorated by Intracerebral Injection of DR5:Fc
Adoptive transfer EAE in SJL mice was induced by intravenous injection of 3 × 107 encephalitogenic PLP-specific lymphocytes, and mean
disease scores were significantly reduced by blockade of TRAIL in the CNS. (A) From the time of T cell transfer, mice were narcotized
intravenously at the indicated intervals (arrowheads), received intracisternal injections of DR5:Fc (n = 5; open circles) or PBS (n = 6; filled
circles), and were monitored for up to 80 days. Mean clinical disease scores were significantly reduced in the DR5:Fc-treated group during
the indicated period [*F12–80(1, 68) = 7.6; p < 0.05, ANOVA]. (B) In order to rule out an unspecific Fc-mediated effect, mice were treated in a
similar way but received either DR5:Fc or Fc fragment only as a control (n = 8 for both groups). Disease was significantly attenuated in
DR5:Fc-treated animals [*F11–20(1, 10) = 5.0; p < 0.05, ANOVA]. For (A) and (B), mean clinical disease scores with SEM are given. (C) Distribution
of DR5:Fc throughout the brain and spinal cord was assessed 2, 6, and 12 hr following injection into the cisterna cerebello-medullaris. A
dispersed signal was found at 6 hr in the cortex, and a strong diffuse signal with the peak at 6 hr was found throughout the spinal cord. Scale
bars, 20 m.to normal human (but not murine) hepatocytes (Jo et i
tal., 2000); human endothelial cells (Li et al., 2003); and
human erythropoietic cells in vitro (Zamai et al., 2000). E
cIn the brain, isolated human oligodendrocytes and hu-
man brain cells preserved in slice cultures were shown p
fto be susceptible to TRAIL (Matysiak et al., 2002; Nitsch
et al., 2000). These findings suggest that TRAIL has an (
tambivalent role in inflammation by promoting anti-
inflammatory mechanisms on the one hand, and by a s
(destructive effector function on the other hand. We
therefore hypothesized that TRAIL acts as a mediator [
nof brain cell death during autoimmune inflammatory
CNS damage. Our experiments involving targeted inhi- c
pbition of TRAIL in the brain and TRAIL-deficient mice
show that the death ligand TRAIL indeed contributes to W
sT cell-induced neuronal pathology in autoimmune neu-
roinflammation. D
D
(Results
f
sTargeted Modulation of TRAIL in the CNS
In view of the existing literature, we hypothesized that t
TRAIL, apart from its reported anti-inflammatory prop-
erties, contributes to the damage mechanisms in EAE. E
IIn order to modulate TRAIL function selectively within
the brain, we injected human TRAIL receptor 2 (TRAIL- W
sR2; DR5) fused to human Fc (DR5:Fc, 1 g in 10 l)ntracisternally (i.c.) at three time points after the adop-
ive transfer of encephalitogenic lymphocytes inducing
AE. This DR5:Fc fusion protein has been shown to re-
ognize mouse TRAIL (Schmaltz et al., 2002), and it
rotects glioma cells (Dörr et al., 2002b) and murine
ibroblasts from TRAIL-mediated apoptosis in vitro
O.A. and F.Z., unpublished data). Indeed, DR5:Fc-
reated mice showed markedly decreased clinical
igns, as compared to PBS-injected control animals
Figure 1A), over a prolonged observation period
F12–80(1, 68) = 7.6; p < 0.05, ANOVA; n = 5 for DR5:Fc;
= 6 for PBS control group]. However, we were con-
erned about a possible nonspecific effect of the Fc
ortion of the DR5:Fc molecule used in this experiment.
e therefore repeated this experiment using the corre-
ponding human Fc protein alone as a control for
R5:Fc and were able to confirm our findings, as
R5:Fc-treated animals showed reduced disease scores
Figure 1B) [*F11–20(1, 10) = 5.0; p < 0.05, ANOVA; n = 8
or both groups]. A time course analysis (2, 6, and 12 hr)
howed distribution of intracisternally injected DR5:Fc
hroughout the brain and spinal cord (Figure 1C).
ffects of Intracerebral DR5:Fc Injections on
mmune Cells in the Brain and outside the Brain
e realized that animals receiving DR5:Fc showed a
lightly earlier disease onset, suggesting a possible
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423systemic immunoregulatory impact of the intracister-
nally applied DR5:Fc, as previously shown by others
(Hilliard et al., 2001). Therefore, we recovered T cells
and macrophages/microglia cells from the brains of
SJL animals transferred with encephalitogenic T cells
and treated with three intracisternal injections of
DR5:Fc or Fc alone. We found that, at the very onset of
the disease (day 7 posttransfer), in the DR5:Fc-treated
animals even more T cells expressed the activation
marker CD25 (Figure 2A). After the peak of the disease,
no differences in the activity of the T cells were further
observed. Absolute numbers and proportion of T cells
and macrophages/microglia cells were comparable at
both time points: at disease onset, the mean total num-
ber of infiltrating cells per mouse (± SEM) was 3.2 ×
106 ± 1.6 for Fc-treated animals and 2.7 × 106 ± 1.4 for
DR5:Fc-treated animals (n = 4 for both groups; p > 0.05,Figure 2. Immunomodulatory Effect and Systemic Distribution of Intracisternal DR5:Fc
(A) T cells and macrophages/microglia cells were isolated from the brain at the onset of the disease (day 7) (mean disability score ± SEM for
DR5:Fc-treated group, 2.63 ± 1.31; for Fc-treated control group, 0.75 ± 0.38; n = 4 for both groups) and at the time of remission (day 14)
(mean disability score ± SEM at the disease peak for DR5:Fc-treated group, 1.95 ± 0.81 [n = 5]; for Fc-treated control group, 2.92 ± 0.60 [n =
6]). Activation markers determined by FACS analysis are given as means with SEM (open bars, treatment with Fc fragment only; filled bars,
treatment with DR5:Fc; *p < 0.05, Mann-Whitney U test).
(B) Spleens and draining cervical lymph nodes were harvested from animals with passive EAE at day 11 after cell transfer. Animals had been
treated with intracisternal DR5:Fc or Fc fragment only, as shown in Figure 1B. Proliferation (given as counts per minute [c.p.m.]) and cytokine
synthesis were measured as described in the Experimental Procedures. Data are presented as means with SD, with each bar corresponding
to four animals treated with Fc fragment only (open bars) or DR5:Fc (filled bars).
(C) In order to check the distribution of the soluble receptor, naive SJL/J animals were intracisternally injected with DR5:Fc and sacrificed 2
and 6 hr later. CNS-draining deep cervical lymph nodes and spleens were isolated and stained for DR5:Fc by immunohistochemistry for the
human Fc fragment of this molecule. Scale bars, 30 m.Mann-Whitney U test). After disease peak, the mean
total number of infiltrating cells per mouse (±SEM) was
2.0 × 106 ± 0.8 for Fc-treated animals (n = 6) and 2.5 ×
106 ± 1.1 for DR5:Fc-treated animals (n = 5; p > 0.05,
Mann-Whitney U test). In a similar experiment, CNS-
draining deep cervical lymph node cells, as well as
splenocytes, were isolated at day 11 posttransfer and
checked for antigen-specific proliferation and cytokine
profiles (IFN-γ and IL-4). However, analysis of these
parameters revealed neither a systemic effect of
DR5:Fc treatment on lymphocyte proliferation nor cy-
tokine synthesis in lymphocytes from deep lymph
nodes or in splenocytes (Figure 2B). We next investi-
gated the body distribution of intracisternally applied
DR5:Fc. This was possible by detection of the human
Fc fragment contained in this recombinant molecule.
We found this fusion protein diffusely distributed in the
Neuron
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pbrainstem up to a maximum of 2 hr after intracisternal
application. At that time point, we detected DR5:Fc a
aconfined to macrophage-like cells in deep cervical
lymph nodes, but not diffusely distributed. After no ds
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Figure 3. Reduced Encephalitogenicity of TRAIL-Deficient Myelin-
Reactive Lymphocytes
MOG-specific lymphocytes from either TRAIL-deficient (ko) or wild- w
type (wt) donors were transferred into wild-type recipients. Disease p
was significantly milder in mice receiving TRAIL-deficient cells W
(filled squares; n = 7), compared to recipients of wild-type cells
e[open squares; n = 11; comparison of mean clinical scores,
pF10–49(1, 40) = 4.9; p < 0.05]. Moreover, disease incidence was sig-
nificantly lower in mice receiving TRAIL-deficient lymphocytes (EAE l
manifestation, i.e., a score of at least 1, was found in one out of w
seven mice), as compared to recipients of wild-type lymphocytes d
(EAE in 9 out of 11). Mean clinical disease scores with SEM are t
shown.
Teficient animals. Subsequently, we transferred these
Figure 4. TRAIL Inhibition Is Associated with Decreased Brain Cell Death in EAE
(A) Brain cells expressing activated caspase 3 were identified by immunohistochemistry (amplified with ABC and visualized with HRP/DAB)
in transverse brainstem sections from animals shown in Figure 1B. Scale bars, 20 m. Sections are from normal (left panel), Fc-treated
(middle panel), or DR5:Fc-treated (right panel) mice, respectively. Arrows point to active caspase 3-positive cells. (B) Average number of
oligodendrocytes and neurons positive for activated caspase 3 in brainstem sections. Each bar represents three mice from the vehicle (Fc)-
treated and DR5:Fc-treated groups, with four sections analyzed per mouse (*p < 0.05, vehicle control-treated compared with DR5:Fc-treated
animals, Mann-Whitney U test). Data show means with SEM. (C) Axonal pathology and areas of demyelination with bars representing five
mice per group (means with SEM; *p < 0.05, Mann-Whitney U test). (D) Neuron from a control (Fc)-treated mouse exhibiting immunolabeling for
activated caspase 3 (aCasp 3) throughout its cytoplasm, which was counterstained with hematoxylin. Arrows point to chromatin condensation
indicating the final phase of apoptosis. (E) Ultrathin section and electron micrograph of apoptotic neuron exhibiting caspase 3 immunolabeling
(DAB; diffuse black precipitates) and morphologic characteristics of apoptosis, i.e., nuclear condensation (white arrowhead) and membrane
blebbing (white arrow; insert). Scale bars, 2.5 m. (F) Light micrograph of TRAIL-expressing cells (dark blue/black signal reflecting DAB/Ni
chromogen) in the vicinity of and in direct contact (arrowheads) with a brainstem neuron in the early phase of apoptosis exhibiting activated
caspase 3 (aCasp 3) staining (brown signal reflecting DAB chromogen; arrows) in its cytoplasm. (G) Semithin section revealing that invading
TRAIL-expressing cells show classical morphological characteristics of lymphocytes (arrowheads). The arrow points to a neighboring cell
exhibiting morphological characteristics of macrophages. Scale bars (D, F, and G), 20 m.ooner than 6 hr, we found DR5:Fc-containing macro-
hage-like cells prominently in the spleen (Figure 2C). A
imilar distribution was found with control Fc injection
lone indicating unspecific uptake of DR5:Fc into
hagocytes, which would rule out a systemic distribu-
ion of soluble DR5:Fc.
ttenuated Passive EAE upon Transfer
f TRAIL-Deficient T Cells
ur data so far suggested that TRAIL plays a detrimen-
al role in effector mechanisms occurring during neu-
oinflammation within the CNS. In view of the pivotal
ole of encephalitogenic T lymphocytes in both initia-
ion of disease and tissue damage (Flugel et al., 2001),
e considered that infiltrating myelin-specific T lym-
hocytes might employ TRAIL as an effector molecule.
e therefore immunized TRAIL-deficient mice (Sedger
t al., 2002) or wild-type C57BL/6 littermates with MOG
eptide 35-55 (MOG35-55) and obtained MOG-reactive
ymphocytes. In MOG-immunized TRAIL-deficient mice,
e found an increased number of CD25+ T cells in
raining lymph nodes on day 13 as compared to wild-
ype (mean percentage ± SEM was 64.8% ± 1.6 for
RAIL-deficient animals versus 51.5% ± 1.4 for wild-
ype littermates; p < 0.05, Mann-Whitney U test; n = 5
er group), whereas no difference in CD44 expression
nd proliferation was observed. Thus, there are indic-
tions of an increased activation of T cells in TRAIL-
Impact of TRAIL on Brain Damage in EAE
425cells upon antigen-specific restimulation into wild-type
C57BL/6 littermates. In this setting, we were able to
closely investigate the roles of TRAIL outside and
within the CNS, as the immunomodulatory function of
TRAIL was preserved in the wild-type recipients. In fact,
these TRAIL-deficient lymphocytes showed a signifi-
cantly reduced capacity to induce EAE: disease mani-
festation and mean clinical scores (Figure 3) were sig-
nificantly milder in mice receiving TRAIL-deficient cells
(EAE incidence: 1 out of 7), compared to recipients of
wild-type cells [EAE incidence, 9 out of 11; comparison
of mean clinical scores, F10–49(1, 40) = 4.9; p < 0.05].
Reduced CNS Damage upon Intracisternal
DR5:Fc Injection
The clinical and immunological data so far suggested
a striking effect of intracisternal DR5:Fc application: al-
though the peripheral antigen response was not al-
tered, DR5:Fc-receiving animals showed a favorable
outcome after the disease peak. We then addressed
the question of whether intracisternal DR5:Fc modu-
lates the inflammatory infiltration within the CNS. How-
ever, we were unable to find a difference, as we ob-
served a comparable number of inflammatory foci/
section corrected for focus size (2.4 ± 0.4 in the
DR5:Fc-treated versus 2.5 ± 0.6 in the Fc-treated con-
trol animals, counted and calculated in four sections
per mouse of three mice from each group in a blinded
manner; p > 0.05, Mann-Whitney U test) (Aktas et al.,
2004). Thus, we assumed that intracisternal DR5:Fc
may have an impact on the tissue damage pattern. In-
deed, immunohistochemical staining for activated cas-
pase 3, a central effector enzyme involved in the execu-
tion of apoptotic cell death, revealed positive neuronsFigure 5. Expression of TRAIL Receptor 2 in the CNS
Brains from naive SJL mice were removed after perfusion with PBS (for RT-PCR and Western blot) or with 4% PFA (for immunohistochemistry)
and tested for the expression of the mouse TRAIL-R2. (A) TRAIL-R2 mRNA expression in selected tissue samples assessed by RT-PCR. (B)
TRAIL-R2 protein expression assessed by Western blot analysis using two different antibodies. (C and D) TRAIL-R2 expression analyzed by
immunohistochemistry in the hippocampus (C) or brainstem (D) of the murine CNS. Arrows point to cells in the brainstem that are clearly
positive. Scale bars, 50 m.with transected neurites (Figure 4A). Quantitative as-
sessment of caspase-positive neurons indicated a sig-
nificant difference between DR5:Fc- or vehicle-treated
animals (Figure 4B). Further, we quantified the caspase-
positive oligodendrocytes in a blinded fashion in the
same way as the neurons. We also found a reduced
number of caspase-positive oligodendrocytes in DR5:Fc-
treated animals, although this difference showed a sta-
tistical trend only (Figure 4B). Moreover, both axonal
pathology determined by APP staining (four longitu-
dinal sections per mouse with five mice per group
assessed in a blinded manner) and demyelination mea-
sured with Luxol fast blue staining (areas were as-
sessed using a MicroBrightField setup; n = 5 mice per
group) were reduced in the DR5:Fc-treated animals
(Figure 4C).
Direct Contact between TRAIL-Expressing Immune
Cells and Apoptotic Neurons during EAE
Our findings so far suggest a role of TRAIL in contribut-
ing to tissue damage during autoimmune neuroinflam-
mation. The comparable immune response in the pe-
riphery and inflammatory infiltration of the brain argued
against a possible indirect, i.e., immunomodulatory, ef-
fect of intracerebral DR5:Fc. We therefore speculated
that TRAIL, released by or localized to infiltrating my-
elin-specific immune cells, may be responsible for
death in TRAIL receptor-bearing target cells during
EAE. We observed that activation of caspase 3 through-
out the cytoplasm of dying brain cells was indeed regu-
larly accompanied by (1) chromatin condensation, as
detected by hematoxylin-eosin counterstaining (Figure
4D), and (2) nuclear condensation and membrane bleb-
bing, as detected by electron microscopy (Figure 4E).
Neuron
426In contrast, apoptotic neurons in normal control mice t
Twere entirely absent. Our immunohistochemical analy-
sis of normal mouse brain showed expression of the n
Sdeath-mediating TRAIL receptor 2 predominantly on
neurons and, to some extent, on oligodendrocytes (Fig- a
aures 5A–5D). Importantly, in the course of EAE, we de-
tected TRAIL-positive lymphocytes that had invaded s
the brain in close vicinity and direct contact with neu- a
rons showing the appearance of caspase 3 activation s
in their cytoplasm (Figures 4F and 4G). These data sug- a
gest that brain-infiltrating and TRAIL-expressing lympho- r
cytes are able to deliver an apoptosis-inducing signal to i
receptor-bearing neurons in the course of neuroinflam- a
mation. 5
s
tRegulation of Intracerebral Expression of TRAIL
(Receptor 2 and TRAIL in the Course of EAE
TIn order to confirm the role of TRAIL in the induction
Aof neuronal apoptosis in vivo, we injected recombinant
tTRAIL into the compartment containing the cerebrospi-Figure 6. Selective TRAIL Susceptibility of the Inflamed CNS
(A) Recombinant human TRAIL (rhTRAIL together with an enhancer antibody for multimerization; open squares) or enhancer antibody alone
(filled squares) were injected intracisternally into healthy mice (arrowheads; n = 5). No clinical deficit was observed. (B and D) Results of
quantitative gene expression analysis for TRAIL receptor 2 (B) and TRAIL (D) performed in different regions of the CNS (brainstem, spinal
cord) from animals with active EAE (induced by immunization with PLP139-151; see Experimental Procedures for details) or from control
animals (sham immunized, i.e., the same immunization protocol as used for active EAE, including pertussis toxin injections, but without
PLP139-151). Animals were analyzed in the course of EAE, i.e., at day 3 (preclinical phase), at day 9 (disease manifestation), or at day 13
(disease peak) after immunization, respectively. Mean relative changes of gene expression assessed with real-time PCR are given (with SEM)
and compared to sham immunized controls (**p < 0.01, Mann-Whitney U test). (C) Quantitative assessment of TRAIL-R2 protein expression
on dentate granule cells in naive controls, Fc-treated passive EAE, and DR5:Fc-treated passive EAE (disease peak for EAE animals). Four
sections from four animals per group were analyzed. Results (mean + SEM) indicate TRAIL-R2 protein expression in relation to naive control
animals (control = 100%) (*p < 0.05, **p < 0.01 for comparison with naive control group, respectively, Mann-Whitney U test). (E) Mild active
EAE was significantly deteriorated by delivery of recombinant human TRAIL into the CNS prior to and at the onset of disease. SJL mice were
immunized and treated with active rhTRAIL (400 ng per mouse) together with enhancer antibody for multimerization (n = 5; open squares;
2 g per mouse) or enhancer antibody alone (n = 5; filled squares) intracisternally at days 6 and 8 after immunization [arrowheads; *F9–47(1,
20) = 6.7; p < 0.05 for comparison of mean clinical scores, ANOVA]. Mean clinical disease scores with SEM are given. (F) Distribution of
recombinant human TRAIL throughout the brain and spinal cord was assessed 2, 6, and 12 hr following injection into the cisterna cerebello-
medullaris. TRAIL was found distributed as far as the cortex and the spinal cord with a peak 6 hr following injection. Scale bars, 20 m.nal fluid. However, even repeated intracisternal injec-ions of recombinant preparations of multimerized human
RAIL induced neither clinical disability nor apoptosis of
eurons and oligodendrocytes, respectively, in healthy
JL mice (Figure 6A). In contrast, the same TRAIL prep-
rations were effective in killing mouse fibroblasts (O.A.
nd F.Z., unpublished data). We therefore assumed that
usceptibility to TRAIL-mediated cell death is differenti-
lly regulated in normal and inflamed murine brain tis-
ue. Supporting this idea, quantitative gene expression
nalysis showed that both the death-mediating TRAIL
eceptor 2 and TRAIL itself are significantly upregulated
n the CNS during EAE (Figures 6B and 6D). Further,
nalysis of protein expression on neurons (Figures 5A–
D) revealed a significant increase of TRAIL-R2 in pas-
ive EAE (both in Fc-injected animals and animals
reated with DR5:Fc in order to block TRAIL signaling)
Figure 6C). Thus, we decided to test intracisternal
RAIL in the course of the inflammatory EAE paradigm.
recombinant TRAIL preparation containing a FLAG
ag was injected together with an enhancer anti-FLAG
antibody for multimerization (Figure 6E). Indeed, as
Impact of TRAIL on Brain Damage in EAE
427Figure 7. DR5:Fc Protects from Encephalitogenic T Cell-Induced Brain Injury In Vitro
(A) Propidium iodide-fluorescence microscopy of the SJL mouse living hippocampal brain slices without (left upper quadrant) or with the
addition of PLP-specific encephalitogenic T cells (left lower quadrant, with Fc control). As a positive control, the hippocampus is shown in
response to application of the neurotoxic agent NMDA (right upper quadrant). Cell death induced by encephalitogenic lymphocytes was
reduced by soluble DR5:Fc (right lower quadrant). Scale bars, 100 m.
(B) The number of PI-positive cells was assessed in the neuronal cell layer of the slice culture incubated with culture medium alone, and with
DR5:Fc or Fc, and with or without encephalitogenic T cells obtained from PLP-immunized SJL mice. An average number of 26 slices was
analyzed per treatment group. Results (means + SEM) indicate cell counts in relation to nondamaged brain tissue (control = 1). The number
of PI+ cells was significantly reduced upon incubation with soluble DR5:Fc (1 g/ml), compared to Fc alone (1 g/ml) or medium control
(*p < 0.05, Mann-Whitney U test).
(C) TRAIL mRNA expression was detected in MOG-specific T cells from wild-type animals but not in TRAIL-deficient T cells. Number of PI-
positive cells (means with SEM) is demonstrated in the neuronal cell layer of CA and DG after invasion of wild-type or TRAIL-deficient MOG-
reactive lymphocytes (*p < 0.05, Mann-Whitney U test).
(D) With confocal laser scanning microscopy, TRAIL expression (blue) is demonstrated by fluorescence labeling of fixed and permeabilized
encephalitogenic T cells using a wide pinhole and aperture for detection (left panel). After invasion into brain tissue (right panel), CFDA-
labeled T cells (green) were found adjacent to dead PI-stained neuronal nuclei (red) surrounded and contacted by secreted TRAIL (blue).
Areas without T cells and neurons do not contain any labeling for TRAIL (circles). Scale bars, 10 m.compared to injection of the enhancer alone, applica-
tion of TRAIL prior to and at the onset of EAE signifi-
cantly increased EAE severity [Figures 6E and 6F;
F9–47(1, 20) = 6.7; p < 0.05 for comparison of clinical
scores, ANOVA; n = 5 for both groups]. Moreover, con-
sidering reports on diverging cytotoxic capacities of
different TRAIL preparations (Lawrence et al., 2001; Qin
et al., 2001), we tested and confirmed this finding (O.A.,
R. Lauster, and F.Z., unpublished data) using a recombi-
nant TRAIL preparation that is active without any en-
hancing antibodies, i.e., N-terminal truncated human
TRAIL (residues 95–281) containing an N-terminal 6-His
tag (Aktas et al., 2004). These results provide evidence
that, during EAE, TRAIL mediates cell death in the CNS
via its specific receptors, which are upregulated under
these inflammatory conditions.
TRAIL-Mediated Neurotoxicity of Encephalitogenic
T Cells In Vitro
In a final set of experiments, we assessed the role of
TRAIL as a mediator of neuronal cell death by encepha-litogenic lymphocytes in living organotypic brain slices.
PLP-specific activated lymphocytes used to induce
transfer EAE were stained with carboxyfluorescein di-
acetate (CFDA) and applied to the surface of these
brain slices (Gimsa et al., 2000). Cell death was visual-
ized by propidium iodide (PI) staining (Figure 7A).
N-methyl-D-aspartate (NMDA)-induced damage in the
pyramidal cell layer of the cornu ammonis (CA) and
granule cell layer of the dentate gyrus (DG) was per-
formed as a positive control. The number of PI+ cells
in the neuronal layer of the CA and DG (for quantifica-
tion, see Ullrich et al., 2001) induced by PLP-restimu-
lated lymphocytes was significantly reduced in the
presence of DR5:Fc(1 g/ml), as compared to their
number in the presence of Fc alone (Figures 7A and
7B). In addition, we employed TRAIL-deficient T cells
and observed significantly reduced neuronal cell death
when compared to wild-type T cells (Figure 7C). In fur-
ther confocal studies, we identified invading CFDA-
labeled T cells in the vicinity of dead neurons whose
DNA was stained by PI (Figure 7D). Importantly, immu-
Neuron
428nolabeling of TRAIL detected by PerCP-Cy5.5 fluores- p
2cence was confined to sites surrounding these invaded
WT cells and dying neurons (Figure 7D). These results
isuggest that both soluble and lymphocyte bound
mTRAIL may contribute to neuronal death in the brain.
t
sDiscussion
f
fFollowing a series of recent findings (Diestel et al.,
2003; Ferguson et al., 1997; Kornek et al., 2000; Meyer
tet al., 2001; Peterson et al., 2001; Trapp et al., 1998),
gneuronal pathology is now considered to be a key fea-
cture of autoimmune neuroinflammation, namely EAE
nand MS. However, the precise mechanisms leading to
dthe destruction of neurons during the myelin-specific
(immune attack have yet to be elucidated.
aThe death ligand TRAIL has primarily aroused tre-
dmendous interest due to its ostensible selectivity in kill-
eing tumor cells, as observed in various animal models
i(Ashkenazi et al., 1999; Cretney et al., 2002; Smyth et
bal., 2001; Walczak et al., 1999). Later, several studies
fincluding our own work (Lünemann et al., 2002; Wan-
cdinger et al., 2003; Wendling et al., 2000) have demon-
sstrated the immunomodulatory capacity of TRAIL in the
aimmune system. Importantly, the blockade of TRAIL ac-
ption outside the CNS results in the exacerbation of vari-
Tous autoimmune disease models (Lamhamedi-Cherradi
cet al., 2003a; Song et al., 2000) including EAE (Hilliard
et al., 2001). These studies propose the potentially ther-
tapeutic use of TRAIL as a protective agent for autoim-
umunity. Surprisingly, it became clear that, apart from
mthese immunomodulatory functions, TRAIL may act as
ba death-inducing effector molecule on nontransformed
(human cells: certain TRAIL preparations were found to
ihave toxic effects on hepatocytes as well as brain cells
t
(Jo et al., 2000; Matysiak et al., 2002; Nitsch et al.,
o
2000). Since we could show that TRAIL is upregulated
o
by activated human lymphocytes (Dörr et al., 2002b;
a
Wendling et al., 2000), we speculated about a potential i
role of TRAIL in the course of the immune cell attack to m
the brain. With these aspects of TRAIL biology in mind, r
we employed strategies for a selective blockade of a
TRAIL within the CNS, which is an anatomically and a
immunologically separate compartment. In fact, in con- c
trast to systemic application of soluble TRAIL receptor f
molecules outside the brain (Hilliard et al., 2001), c
DR5:Fc injection selectively into this compartment re- c
sulted in an amelioration of EAE. We were able to show i
that our intracisternal route of injection did not influ- o
ence the peripheral immune response including T cell e
proliferation and cytokine release. Furthermore, transfer i
of myelin-specific TRAIL-deficient T cells into wild-type e
recipients yielded a significantly attenuated disease m
score. In this experimental setting, the peripheral im- r
munomodulatory role of TRAIL was preserved, as re- m
cipient wild-type animals were still able to regulate the (
transferred T cells via TRAIL. These findings indicate w
that brain-invading myelin-specific T cells (Flugel et al., s
2001) that lack the important effector molecule TRAIL o
are significantly reduced in their damaging capacity. An a
initial increase in T cell activity in the brain following
CNS-specific blockade of TRAIL signaling is in line with f
pthe anti-inflammatory capacity of TRAIL as earlier re-orted for the peripheral immune system (Hilliard et al.,
001; Lünemann et al., 2002; Wandinger et al., 2003).
e conclude that TRAIL plays an ambivalent role dur-
ng EAE: extracerebrally, i.e., within the peripheral im-
une system, TRAIL has an anti-inflammatory (and
hus protective) effect, whereas in the central nervous
ystem this anti-inflammatory effect is less important
or EAE outcome than the apoptosis-inducing effector
unction targeting neural cells.
Our analysis of healthy CNS tissue revealed that main
argets during neuroinflammation, i.e., neurons and oli-
odendrocytes, express the death-mediating TRAIL re-
eptor 2 (Dörr et al., 2002a). In contrast, TRAIL itself is
ot expressed within the brain (Dörr et al., 2002a). In-
eed, soluble TRAIL, when applied to living CNS tissue
Nitsch et al., 2000) or oligodendrocytes (Matysiak et
l., 2002), can induce caspase-dependent brain cell
eath. Thus, it may well be the case that TRAIL-
xpressing activated T cells that invade the brain dur-
ng neuroinflammation (Flugel et al., 2001) mediate
rain damage using TRAIL as an effector molecule. In
act, we observed that caspase-dependent neuronal
ell death in the course of EAE (Diestel et al., 2003) was
ignificantly reduced by blocking TRAIL within the CNS
s shown by our present data. In our study, caspase-
ositive neurons were frequently contacted by small,
RAIL-expressing lymphocytes, favoring T cells as the
ellular source of TRAIL.
We and other investigators have previously shown
hat (1) TRAIL is upregulated on the surface of T cells
pon antigen-specific stimulation (Mariani and Kram-
er, 1998; Wendling et al., 2000), (2) TRAIL is secreted
y activated T cells (Martinez-Lorenzo et al., 1999), and
3) TRAIL plays a significant role in T cellular cytotoxic-
ty (Dörr et al., 2002b). Our in vitro studies using organo-
ypic slices show that myelin-specific T cells invading
rganotypic slice cultures release TRAIL in the vicinity
f dying neurons. In fact, these encephalitogenic T cells
re able to induce substantial neuronal damage. This is
n line with recent reports by Giuliani et al. reporting a
arked toxicity of human T cells toward human neu-
ons in vitro (Giuliani et al., 2003). In the present study,
ctivated TRAIL-deficient lymphocytes from knockout
nimals showed a significant reduction in their killing
apacity. Using 2-photon laser scanning microscopy
or live imaging in slices (Nitsch et al., 2004), we re-
ently observed that TRAIL-deficient T cells directly
ontact neurons but show a reduced neurotoxic capac-
ty (O.A., E.P., R.N., and F.Z., unpublished data). More-
ver, functional blockade of TRAIL using DR5:Fc was
ffective in preventing this neuronal cell death, indicat-
ng a pivotal role of TRAIL in damage processes. How-
ver, it is possible that TRAIL secreted by infiltrating
acrophages may contribute to TRAIL-mediated neu-
al damage in EAE, as we recently identified activated
acrophages as a significant source of soluble TRAIL
Ehrlich et al., 2003). This is supported by Miura et al.,
ho have demonstrated the involvement of the TRAIL
ystem in macrophage-mediated neuronal cell death
ccurring in a humanized mouse model of HIV-associ-
ted encephalopathy in vivo (Miura et al., 2003).
Interestingly, we could not discern any cytotoxic ef-
ects in connection with either of two different TRAIL
reparations applied intracisternally in healthy animals.
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429This observation is in line with a previous report dem-
Tonstrating that intracerebral injection of TRAIL in a xe-
nograft brain tumor model only affects the tumor cells
and does not show significant neurotoxicity to the nor-
mal CNS tissue (Roth et al., 1999). However, a recent
report showed that TRAIL, which lacks any hepatotox-
icity in healthy rodents, critically contributes to hepato-
cyte cell death in different models of murine hepatitis
(Zheng et al., 2004). We therefore performed quantita-
tive expression analysis for TRAIL receptor 2 and found
a significant upregulation prior to and during the peak
phase of EAE. Accordingly, we observed that intracis-
ternally applied soluble TRAIL enhanced disease sever-
ity in animals with ongoing EAE, while healthy animals
were not affected. This indicates that receptor levels
under normal conditions are not sufficient to mediate a
significant death signal, which is only achieved in the
course of inflammation. Indeed, inflammation itself was
not modulated by intracerebral TRAIL blockade, and
this further corroborates the idea that TRAIL is a spe-
cific death-inducing effector molecule in the brain. This
finding might also explain why the use of TRAIL for tu-
mor therapy did not result in toxic effects to healthy
neurons.
Taken together, our study reveals that the death li-
gand TRAIL critically contributes to irreversible CNS
damage during autoimmune neuroinflammation. Evi-
dence is provided for an important role of TRAIL ex-
pressed on and secreted by CNS-invading lympho-
cytes in the effector phase of a multiple sclerosis
animal model. One has to bear in mind, however, that
the immunosuppressive properties of TRAIL may be
useful to enhance the effects of TRAIL outside the CNS.
This complex action of TRAIL resembles a double-
edged sword, as known for other members of the TNF
family such as the CD95 system (Zipp et al., 1999).
However, targeted modulation of TRAIL receptor-TRAIL
interactions within the inflamed brain may represent a
possible therapeutic strategy for the prevention of neu-
rological deficits in MS patients.
Experimental Procedures
PCR
Reverse Transcriptase PCR
Total RNA was isolated from PBS-perfused frozen tissue followed
by digestion with DNase I. PCR conditions were as follows: 30 cy-
cles, 30 s/95°C, 30 s/65°C, 45 s/72°C; TRAIL-R2 primer sequences
(GenBank AF176833) 5#-CACAAATACGGTGTGTCGATG-3# (nucleo-
tides 372–392) and 5#-CTGGAACCAGGAGTCCTATCC-3# (nucleo-
tides 551–571); TRAIL primer sequences (Genbank NM009425) 5#-
TGAGGATTTCTGGGACTCCACTGA-3# (nucleotides 241–264) and
5#-CTTCAGCTTCCTGAAATCGG-3# (nucleotides 628–647); β-actin
primer sequences (GenBank J04181) 5#-GTGGGCCGCCCTAGG
CACCA-3# (nucleotides 165–184) and 5#-CGGTTGGCCTTAGGGTT
CAGGGGG-3# (nucleotides 386–409). Isolated PCR fragments were
reamplified and checked with an ABI 377 DNA sequencing system
(Applied Biosystems, Weiterstadt, Germany).
Quantitative Real-Time PCR
For quantitative real-time PCR, reverse transcription and Taqman
real-time PCR analysis was done in duplicate using the 2-CT
relative quantification method (ABI-Prism 7700, Applied Biosys-
tems). PCR conditions: 2 min at 50°C, 10 min at 95°C, followed by
40 cycles, 15 s/95°C, 60 s/60°C. The following PCR primers and
fluorogenic probes (Eurogentec, Seraing, Belgium; designed with
Primer Express Software, Applied Biosystems) were used: TRAIL
forward, 5#-GATCACTCGGAGAAGCAACTCA-3#; TRAIL reverse, 5#-GAGAGGACTCCCAGGATT-CAATC-3#; TRAIL probe, 5#-FAM-CAA
CTCCAAGGATGGAAAGACCTTAGGCCA-TAMRA-3#; TRAIL-R2
forward, 5#-TGCAAACCAGGCACCTTTG-3#; TRAIL-R2 reverse, 5#-
TCT-TCCCCGTCAGTGCAGTT-3#; TRAIL-R2 probe, 5#-FAM-AGACT
CCCCTGAGATC-TGCCAGTCATGCT-TAMRA-3#; GAPDH forward,
5#-CTCAACTACATGGTCTACAT-GTTCCA-3#; GAPDH reverse, 5#-
CCATTCTCGGCCTTGACTGT-TAMRA-3#; GAPDH probe, 5#-FAM-
TGACTCCACTCA CGGCAAATTCAACGT-TAMRA-3#.
Western Blot
PBS-perfused frozen tissue or lymphocytes were homogenized in
extraction buffer containing 1% Triton X-100 and protease inhibi-
tors (0.2 mM PMSF, 1 g/ml pepstatin, 0.5 g/ml leupeptin). Sam-
ples were separated by 12% SDS-PAGE, membranes were incu-
bated with anti-TRAIL-R2 antibodies (dilution 1:1000; AB1687 or
AB16942; Chemicon, Temecula, CA). Antibodies coupled to horse-
radish peroxidase (Dako Diagnostica, Hamburg, Germany) were
used as secondary antibodies, and an ECL-plus system (Amer-
sham Pharmacia, Freiburg, Germany) was used for development.
Membranes were sequentially incubated with an antibody against
β-actin (Sigma, Deisenhofen, Germany).
Histology and Immunohistochemistry
Mice euthanized with narcotics were transcardially perfused with
4% paraformaldehyde (PFA). Horizontal 50 m thick vibratome sec-
tions (Shandon, Pittsburgh, PA) or 10 m thick paraffin sections
were immersed with 3% H2O2 to quench unspecific endogenous
peroxidase activity, then washed and blocked (10% normal serum
and 0.5% Triton X-100) prior to overnight incubation with anti-acti-
vated caspase 3 (1:100; R&D, Wiesbaden, Germany), anti-TRAIL-
R2 antibody (Ab16942; 1:50; Chemicon), or anti-β-APP (1:1000;
Zymed Laboratories, San Francisco, CA). Sections were immuno-
stained using FITC-labeled secondary antibodies or the avidin:bio-
tinylated enzyme complex technique (ABC-Elite, Vector Laborato-
ries, Burlingame, CA) before development with diaminobenzidine
([DAB]; brown signal) as a substrate. Ig-control experiments were
performed for all primary antibodies, and no staining was observed
under these conditions. Axonal ovoids indicating transection (Aktas
et al., 2004) were counted in longitudinal spinal cord sections (cer-
vical to lumbosacral level; five sections per mouse). Areas of de-
myelination were quantitatively evaluated using Luxol fast blue
staining (American Histolabs, Gaithersburg, MD). Cell-specific ex-
pression of TRAIL-R2 was assessed as immunofluorescence signal
intensity on vibratome sections using a MetaMorph analysis setup.
For counterstaining of nuclei, brainstem sections stained for active
caspase 3 were incubated with Harris hematoxylin for 1 min at
room temperature. For the staining of TRAIL, these sections were
labeled with mouse DR5:human Fc chimera (1:25; R&D) and visual-
ized using DAB/Ni as a chromogen (dark blue/black signal), as de-
scribed elsewhere (Leranth and Nitsch, 1994). Electron microscopy
was performed on a Zeiss EM 900 (Jena, Germany).
Induction of Active and Passive EAE, Treatment Procedures,
and Distribution Analysis
For adoptive transfer (passive) EAE in SJL mice, female donors
(6–8 weeks; Harlan, Rehovot, Israel; Charles River, Sulzfeld, Ger-
many) were immunized with murine PLP139-151 (purity > 95%;
Pepceuticals, Leicester, UK) as previously described (Steinbrecher
et al., 2001). Primary lymph node cells were prepared 10 days later,
restimulated with PLP139-151 (10 g/ml) for 4 days, and injected
intravenously (i.v.) into syngenic recipients (3 × 107 cells per
mouse). Antigen specificity of injected cells was routinely checked
with a standard 3[H]-thymidine proliferation assay. For active EAE
in SJL mice, animals were immunized as previously described (Ak-
tas et al., 2003; Aktas et al., 2004) with the following modifications:
each mouse received 100 g PLP139-151 in complete Freund adju-
vant (CFA; supplemented with M. tuberculosis H37Ra, 2 mg/ml),
and pertussis toxin (200 ng per mouse; List) was injected intraperi-
toneally at days 0 and 2 after immunization. The control group for
serial assessment of gene expression in the course of active EAE
(Figures 6B and 6D) was sham immunized, i.e., using the same
immunization protocol as for active EAE, including pertussis toxin
injections, but without PLP139-151. For passive EAE in TRAIL-defi-
Neuron
430cient animals, C57BL/6 TRAIL knockout mice (kindly provided by l
uAmgen, Seattle, WA) (Cretney et al., 2002; Sedger et al., 2002) and
wild-type littermates were immunized with MOG35-55 (purity f
c>95%; Pepceuticals; in CFA supplemented with M. tuberculosis
H37Ra, 4 mg/ml). Twelve days later, animals were sacrificed, s
owhereupon draining lymph node cells were isolated, restimulated
with MOG35-55 (30 g/ml) in the presence of IL-12 (20 ng/ml, p
wR&D), harvested after 72 hr, and injected into wild-type recipients
(20 × 106 blasts per mouse). Pertussis toxin (400 ng per mouse) m
lwas administered at day 0 and 2 after immunization. For all EAE
procedures, neurological deficits were graded as previously de- e
escribed (Aktas et al., 2003). For intracisternal treatment procedures,
mice were intravenously anesthetized with ketamine (50 mg/kg; w
eCuramed, Karlsruhe, Germany) and xylazine (10 mg/kg; Bayer, Le-
verkusen, Germany) before puncture of the cisterna magna with a t
T26G syringe (Hamilton, Bonaduz, Switzerland). Human recombinant
DR5:Fc (1 g per mouse) or vehicle control (1 g human Fc for r
iFigure 1B or PBS alone for Figure 1A; see text and figures for ex-
planation) was injected in a volume of 10 l (Okuda et al., 1998;
Reijneveld et al., 1999; Saeki et al., 1992). Human Fc fragment was S
Fobtained from Calbiochem (San Diego, CA) and dialyzed against
sterile PBS before use. Similarly, recombinant human TRAIL (400 c
sng with 2 g enhancer antibody for multimerization per mouse;
Alexis, San Diego, CA) or vehicle control (enhancer antibody alone) p
was injected intracisternally in a total volume of 10 l. Distribution
of DR5:Fc or Fc was assessed in sections of brain, lymph nodes,
Aand spleen using anti-human Fc fragment antibody (Sigma) and
FITC or ABC/DAB for visualization. TRAIL was visualized using a
DR5:Fc-FITC detection system (Alexis). All procedures were con- T
fducted according to protocols approved by the local animal wel-
fare committees. F
t
rIsolation of CNS Mononuclear Cells and FACS Analysis
NIsolation of CNS mononuclear cells was performed basically as
tpreviously described (Ford et al., 1995; Mack et al., 2003), with mi-
vnor adaptations: tissue digestion was performed in DMEM contain-
ming 363 U/ml clostridiopeptidase A (Sigma) and 200 U/ml DNase I
(Roche, Mannheim, Germany) for 30 min at 37°C. Homogenate was
resuspended in 23% Percoll (Amersham Pharmacia) and underlain R
with 73% Percoll. The gradients were centrifuged for 30 min. Phe- R
notypic analysis of the infiltrate was performed using a FACSCali- A
bur (Becton Dickinson, Heidelberg, Germany). Activation of T cells P
was monitored as described previously (Nitsch et al., 2004) using
antibodies against CD3, CD25, and CD44. Activation of CNS- R
derived macrophages was analyzed by monitoring the expression
of ICAM-1 on nonlymphocytic CD11b-positive cells (all antibodies A
from BD Pharmingen, Heidelberg, Germany). z
(
mEx Vivo Proliferation
Lymph node cells and splenocytes were isolated as previously de- 1
scribed (Brocke et al., 1996). After 72 hr culture with PLP (5 or 25 A
g/ml) or concanavalin A (ConA; 2 g/ml), 0.5 Ci 3[H]-thymidine L
was added to each well, and 18 hr later incorporation was mea- F
sured in counts per minute (c.p.m.) with a Microbeta counter (Wal- N
lac, Freiburg, Germany). c
A
Cytokines t
For detection of IFN-γ or IL-4, sandwich ELISAs of supernatants (
were performed according to the manufacturer’s instructions (Bec- l
ton Dickinson).
B
p
Coculture of Slices and T Cells p
Organotypic entorhinal-hippocampal slice cultures (350 m thick)
Bfrom 10-day-old SJL or C57BL/6 mice were prepared on a tissue
Ichopper (Bachhofer, Reutlingen, Germany) and cultured as de-
tscribed (Ullrich et al., 2001). For coculture, 5 × 104 encephalitogenic
mlymphocytes (as used for EAE induction) were prelabeled with
BCFDA (Gimsa et al., 2000) and transferred to the surface of slices
j(day 7 in vitro) preincubated with DR5:Fc or Fc alone (both 1 g/
ml) for 3 hr. NMDA (50 M) was applied as a positive control. En- C
acephalitogenicity of PLP-specific lymphocytes was routinely
checked by successful induction of adoptive transfer EAE. Damage a
min neuronal cell layers of the CA and DG was detected 12–24 hrater by adding 5 g/ml PI (30 min at 36°C) (Ullrich et al., 2001)
sing a rhodamine filter (488 nm/515 nm) with a dark-field inverse
luorescence microscope (Olympus, Tokyo, Japan). Dead lympho-
ytes were distinguished by double-fluorescence microscopy and
ubtracted from the counts of PI+ cells within the neuronal layers
f the slices. For resectioning, slices were immersed prior to the
reparation of 20 m thin horizontal cryostat sections. Brain slices
ere fixed using the same fixative and were treated as whole
ounts in the same way as with vibratome sections. For confocal
aser scanning microscopy, CFDA and PI were excited at 488 nm,
mission of CFDA was detected between 510 and 560 nm, and
mission of PI was detected between 570 nm and 625 nm. TRAIL
as immunostained with the M19 antibody (Santa Cruz, CA) (Dörr
t al., 2002a) and labeled with PerCP-Cy5.5 fluorescence dye (exci-
ation at 633 nm, detected between 680 and 710 nm) using a Leica
CS SP2 confocal microscope (Leica, Heidelberg, Germany). Cor-
esponding Ig-control experiments were performed, and no stain-
ng was observed under these conditions.
tatistics
or group comparisons, the Mann-Whitney U test was applied. To
ompare the EAE courses, statistical analysis of repeated mea-
urements was performed by means of variance using the Fisher’s
airwise least significant difference test (Aktas et al., 2003).
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